Is there any treatment for inflammatory amyloidosis?

Joint Bone Spine

Volumn 78, Issue 1, 2011, Pages 7-9

  Stankovic, Katia ^a   Grateau, Gilles ^a  

^a HÔPITAL TENON   (France)

Author keywords

AA amyloidosis; Cytokine inhibitor; Inflammatory amyloidosis; Serum amyloid A

Indexed keywords

AMYLOID P COMPONENT; ANTIINFLAMMATORY AGENT; AZATHIOPRINE; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 6;

AGED; AMYLOIDOSIS; ANKYLOSING SPONDYLITIS; EDITORIAL; FOLLOW UP; GENE MUTATION; HUMAN; INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; NONHUMAN; PROGNOSIS; SURVIVAL;

AMYLOIDOSIS; ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION;

EID: 78651084860     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.09.001     Document Type: Editorial

References (25)

1. Hazenberg B.P., van-Rijswijk M.H., Amylose A.A. Les amyloses 2000, Flammarion Médecine-Sciences, Paris, p. 377-427. G. Grateau, M.D. Benson, M. Delpech (Eds.).
2. Magy-Bertrand N., Dupond J.L., Mauny F., et al. Incidence of amyloidosis over 3 years: the AMYPRO study. Clin Exp Rheumatol 2008, 26:1074-1078.
3. Immonen K., Finne P., Hakala M., et al. No improvement in survival of patients with amyloidosis associated with inflammatory rheumatic diseases -- data from the Finnish national registry for kidney diseases. J Rheumatol 2008, 35:1334-1338.
4. Lachmann H.J., Goodman H.J., Gilbertson J.A., et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med 2007, 356:2361-2371.
5. Bollée G., Guery B., Joly D., et al. Presentation and outcome of patients with systemic amyloidosis undergoing dialysis. Clin J Am Soc Nephrol 2008, 3:375-381.
6. Cazeneuve C., Ajrapetyan H., Papin S., et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. Am J Hum Genet 2000, 67:1136-1143.
7. Touitou I., Sarkisian T., Medlej-Hashim M., et al. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum 2007, 56:1706-1712.
8. Grateau G., Jéru I., Rouaghe S., et al. Amyloidosis and auto-inflammatory syndromes. Curr Drug Targets Inflamm Allergy 2005, 4:57-65.
9. Lachmann H.J., Gilbertson J.A., Gillmore J.D., et al. Unicentric Castleman's disease complicated by systemic AA amyloidosis: a curable disease. QJM 2002, 95:211-218.
10. Millet A., Rioux-Leclercq N., Le Lay J.P., et al. Unexpected remission of renal AA amyloidosis associated with rheumatoid arthritis. Joint Bone Spine 2009, 76:431-432.
11. Chevrel G., Jenvrin C., McGregor B., et al. Renal type AA amyloidosis associated with rheumatoid arthritis: a cohort study showing improved survival on treatment with pulse cyclophosphamide. Rheumatology (Oxford) 2001, 40:821-825.
12. Gottenberg J.E., Merle-Vincent F., Bentaberry F., et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthritis Rheum 2003, 48:2019-2024.
13. Fernandez-Nebro A., Tomero E., et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. Am J Med 2005, 118:552-556.
14. Perry M.E., Stirling A., Hunter J.A. Effect of etanercept on serum amyloid A protein (SAA) levels in patients with AA amyloidosis complicating inflammatory arthritis. Clin Rheumatol 2008, 27:923-925.
15. Keersmaekers T., Claes K., Kuypers D.R., et al. Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. Ann Rheum Dis 2009, 68:759-761.
16. Kuroda T., Otaki Y., Sato H., et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with infliximab. Rheumatol Int 2008, 28:1155-1159.
17. Thornton B.D., Hoffman H.M., Bhat A., et al. Successful treatment of renal amyloidosis due to familial cold autoinflammatory syndrome using an interleukin 1 receptor antagonist. Am J Kidney Dis 2007, 49:477-481.
18. Leslie K.S., Lachmann H.J., Bruning E., et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006, 142:1591-1597.
19. Lachmann H.J., Kone-Paut I., Kuemmerle-Deschner J.B., et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Engl J Med 2009, 360:2416-2425.
20. Nishida S., Hagihara K., Shima Y., et al. Rapid improvement of AA amyloidosis with humanised anti-interleukin 6 receptor antibody treatment. Ann Rheum Dis 2009, 68:1235-1236.
21. Dember L.M., Hawkins P.N., Hazenberg B.P., et al. Eprodisate for the treatment of renal disease in AA amyloidosis. N Engl J Med 2007, 356:2349-2360.
22. Pepys M.B., Herbert J., Hutchinson W.L., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 2002, 417:254-259.
23. Browning MJ, Banks RA, Tribe CR et al. Ten years' experience of an amyloid clinic - a clinicopathological survey. Q J Med 1985;54:213-27.
24. Joss N, McLaughlin K, Simpson K et al. Presentation, survival and prognostic markers in AA amyloidosis. QJM 2000;93:535-42.
25. Tuglular S, Yalcinkaya F, Paydas S et al. A retrospective analysis for aetiology and clinical findings of 287 secondary amyloidosis cases in Turkey. Nephrol Dial Transplant 2002;17:2003-5.